# Targeted drug shrinks tumors in 3 out of 4 patients with advanced breast cancer

- URL: https://talkfuse.com/story/targeted-drug-shrinks-tumors-in-3-out-of-4-patients-with-advanced-breast-cancer/
- Published: 2026-10-29T17:14:26+00:00
- Updated: 2026-11-04T05:12:07+00:00
- Original publisher: Fox News (publisher lean: Right)
- Original article: https://www.foxnews.com/health/targeted-drug-shrinks-tumors-3-out-4-patients-advanced-breast-cancer
- Topics: Americas, Health, Medicine, Mental Health, Research, Science, World

## Key points

- The drug extended median time without progression to 16.4 months.
- Tumours shrank in 75.5% of patients treated with it.
- Serious side effects were more common than with chemotherapy.

## Summary

A phase three trial found that trastuzumab rezetecan delayed tumour growth more than standard chemotherapy in women with advanced breast cancer whose tumours have low levels of HER2. The findings suggest the drug could offer patients longer before their cancer worsens, including across hormone receptor-positive and hormone receptor-negative disease.

The study randomly assigned 551 women at 73 hospitals in China to receive the drug every three weeks or a doctor’s choice of chemotherapy, between June 2023 and August 2025. Median time before the cancer progressed was 16.4 months with the drug and 6.8 months with chemotherapy; tumours shrank in 75.5% and 41.2% of patients respectively. Serious side effects were reported in more than 84% of those given the drug, against nearly 68% receiving chemotherapy, and researchers said further study is needed.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.